Company news

Oxford BioMedica plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Total Voting Rights

November 2, 2026

Appointment of Independent Non-Executive Director

October 16, 2026

Admission to Trading

October 9, 2026

PDMR Dealing

October 6, 2026

Admission to Trading

October 6, 2026

Grant of Award

October 2, 2026

Total Voting Rights

October 1, 2026

Oxford Biomedica Advances Global Quality Transformation with Veeva Quality Cloud

September 23, 2026

Half Year Trading Update and Notice of Results

August 7, 2026

OXB Selected as GMP Manufacturing Partner to Support Manufacturing of Plowshare Therapies’ AAV Gene Therapy Programme

July 16, 2026

Manufacturing agreement with Plowshare Therapies

July 16, 2026

Admission to trading application

June 17, 2026

OXB Capital Markets Event

June 2, 2026

OXB to exhibit and present at the 30th Annual Meeting of the American Society of Cell and Gene Therapy (ASGCT)

May 8, 2026

Launch of viral vector fast-track offering

April 13, 2026

Grant of Awards

April 8, 2026

2026 Annual General Meeting notification

March 30, 2026

Preliminary results for the year ended 31 Dec 2025

March 26, 2026

Licensing agreement with VVMF

March 18, 2026

Admission to Trading

March 9, 2026

Admission to Trading Application

March 4, 2026

Capital Markets Day and investor conferences

March 3, 2026

Total Voting Rights

March 2, 2026

Response to Rule 2.8 Announcement

February 25, 2026

Disclosure Table

February 25, 2026

Rule 2.8 Announcement

February 25, 2026

Full year Trading Update and Notice of Results

February 24, 2026

Rule 2.9 Announcement

February 19, 2026

Extension of PUSU Deadline

February 11, 2026

Multi-year supply agreement with BMS

February 4, 2026

Response to press speculation

January 14, 2026

Block Listing Return

January 2, 2026

PDMR Dealing

December 8, 2025

Holding(s) in Company

November 3, 2025

OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

October 29, 2025

OXB honoured at 2025 CDMO Leadership Awards Europe

October 29, 2025

OXB to participate in upcoming investor conferences and events

October 27, 2025

OXB to participate in investor conferences

October 27, 2025

Director/PDMR Shareholding

October 20, 2025

Board Change

October 20, 2025

OXB expands US footprint with acquisition of commercial-scale viral vector facility in North Carolina

October 7, 2025

Acquisition of US viral vector facility

October 7, 2025

Interim Results for 6 months ended 30 June 2025

September 23, 2025

PDMR Dealings

August 22, 2025

Admission of Shares and Total Voting Rights

August 20, 2025

Results of Placing

August 15, 2025

Proposed Placing of New Ordinary Shares

August 14, 2025

OXB Secures New Loan Facility with Oaktree

August 1, 2025

Half Year Trading Update

July 28, 2025

Director Declaration

July 2, 2025

Older news releases →

Calls

The 5 newest of 8 calls. Every call is listed under its year.

Decks

The 5 newest of 23 decks. Every deck is listed under its year.